Benzinga | Dec 14, 2021 05:41AM EST

Credit Suisse Downgrades Arena Pharmaceuticals to Neutral, Raises Price Target to $100

Credit Suisse analyst Martin Auster downgrades Arena Pharmaceuticals (NASDAQ:ARNA) from Outperform to Neutral and raises the price target from $98 to $100.